Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234116 · ClinicalTrials.gov registry record · Phase 4
Post-Exposure Prophylaxis in Health Care Workers
A Phase 4 study of Human Immunodeficiency Virus, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT01234116 is a Phase 4 study of Human Immunodeficiency Virus that has completed, run by Henry Ford Health System. The registered enrollment target is 16 participants, below the 184-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01234116, a Phase 4 study of Human Immunodeficiency Virus, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
Objective: The objective of this study is to determine the safety and tolerability of Post-exposure Prophylaxis (PEP) with a regimen of Truvada + Kaletra among health care workers (HCWs) at Henry Ford Hospital. Hypothesis: Raltegravir is safe and better tolerated compared with Kaletra, each in combination with Truvada, as assessed by review of completion rates of PEP and also review of completed safety data.
Conditions Studied
Interventions
- DRUG emtricitabine/tenofovir disoproxil fumarate
Study Locations (1)
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-02 |
| Est. Completion | 2013-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234116
The ClinicalTrials.gov registry entry for NCT01234116 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (91% lower). The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which emtricitabine/tenofovir disoproxil fumarate is the first listed.
NCT01234116 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01234116 about?
NCT01234116 is a clinical study titled "Post-Exposure Prophylaxis in Health Care Workers". Objective: The objective of this study is to determine the safety and tolerability of Post-exposure Prophylaxis (PEP) with a regimen of Truvada + Kaletra among health care workers (HCWs) at Henry Ford Hospital. Hypothesis: Raltegravir is safe and better tolerated compared with Kaletra, each in comb...
What is the current status of trial NCT01234116?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2011-02. Estimated completion is 2013-05.
What conditions does trial NCT01234116 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus.
What interventions are being tested in trial NCT01234116?
The interventions under investigation include: emtricitabine/tenofovir disoproxil fumarate (DRUG).
Who is sponsoring clinical trial NCT01234116?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01234116 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Low Dose Naltrexone for Pain in Patients With HIV
RECRUITING · Phase 4
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Biomarkers for Event-driven PrEP Adherence
COMPLETED · Phase 4
-
Switching Undetectables to Selzentry
COMPLETED · Phase 4
-
HIV Non-Occupational Post-Exposure Prophylaxis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.